Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | AGER | Q15109 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18784138 | 0.97 | COMT (0.48) | COMTTSHRHTTKDM4EMAPT | |
| Potassium Ion SCHEMBL18784160 | 0.97 | COMT (0.48) | COMTTSHRHTTKDM4EMAPT | |
| Lithium Ion SCHEMBL18784188 | 0.89 | TSHR (0.42) | COMTTSHRHTTKDM4EMAPT | |
| Lithium Ion SCHEMBL18784179 | 0.87 | TSHR (0.40) | COMTTSHRHTTKDM4EMAPT | |
| Potassium Ion SCHEMBL18784182 | 0.86 | TSHR (0.42) | COMTTSHRHTTKDM4EMAPT | |
| SCHEMBL18784122 | 0.86 | TSHR (0.42) | COMTTSHRHTTKDM4EMAPT | |
| Potassium Ion SCHEMBL18784201 | 0.84 | TSHR (0.40) | COMTTSHRHTTKDM4EMAPT | |
| SCHEMBL18784204 | 0.84 | TSHR (0.40) | COMTTSHRHTTKDM4EMAPT | |
| SCHEMBL16834249 | 0.83 | COMT (0.50) | COMTTSHRHTTKDM4EMAPT | |
| Lithium Ion SCHEMBL18784121 | 0.83 | PABPC1 (0.40) | TSHRKDM4EMAPTNPSR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3162795-B1 | METHOD FOR MANUFACTURING 3-(ALKYL SULFONYL)PYRIDINE-2-CARBOXYLIC ACID | SUMITOMO CHEMICAL CO (JP) | 2019-07-31 | — | — | EP | disclosed |
| US-9815786-B2 | Method for manufacturing 3-(alkylsulfonyl)pyridine-2-carboxylic acid | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-11-14 | — | — | US | disclosed |
| US-20170129859-A1 | METHOD FOR MANUFACTURING 3-(ALKYLSULFONYL)PYRIDINE-2-CARBOXYLIC ACID | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-05-11 | — | — | US | disclosed |
| EP-3162795-A1 | METHOD FOR MANUFACTURING 3-(ALKYL SULFONYL)PYRIDINE-2-CARBOXYLIC ACID | Sumitomo Chemical Company, Limited (JP) | 2017-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129859-A1 | METHOD FOR MANUFACTURING 3-(ALKYLSULFONYL)PYRIDINE-2-CARBOXYLIC ACID | STS, SRM, CERS2 | COMT 3319/4885TSHR 957/4885HTT 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.